Boy with Bike)

For Patients

Our Promise to Patients: You Come First

Welcome home

You've likely had a long journey, but now you're among friends. We understand serious and rare diseases because we've specialized in them for decades and we're here to help. By working closely with people like Logan and his family (pictured above), we're able to identify and pursue new innovations that address unmet medical needs. Meanwhile, we continue to enhance our current treatments for rare diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, hereditary angioedema, and Alpha 1 antitrypsin deficiency.   

We are driven by our promise to save lives and improve the quality of life for our patients and their families, because living with a rare disease impacts more than just one person. We offer support programs and activities and we partner with patient advocacy organizations to improve and expand educational and outreach efforts. We also work with government authorities to ensure patients have access to the medicines they need to live life to the fullest.

How can we help you?

Immunodeficiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Hereditary Angioedema (HAE)

We introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Alpha 1 Antitrypsin Deficiency

Our Alpha 1 proteinase inhibitor treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with Alpha 1-related emphysema.

Machelle Pecoraro HAE Machelle Pecoraro HAE

" Never give up and never give in. You can overcome this and find a way to do all you ever dreamt possible. "

- HAE Patient Machelle Pecoraro

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area Condition Description
Haematology and Thrombosis
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Hemophilia B A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Hemophilia A & B Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors Terminated
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
Von Willebrand Disease Study of Voncento® in Subjects With Von Willebrand Disease Completed
Reversal of acquired coagulation factor deficiency An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding Learn More
Cardiovascular and Metabolic Acute Coronary Syndrome  Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Learn More
  Coronary Heart Disease Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Completed
Immunology and Neurology Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Results
  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) Learn More
  Pediatric CIDP Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Learn More
  Hereditary Angioedema (HAE) A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Learn More
  Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Completed
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Results
  Primary Immune Deficiency (PID) Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump Learn More
  Healthy Subjects Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults Learn More
Healthy Subjects Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
Transplant Antibody-mediated kidney transplant rejection Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Learn More
  Acute GVHD (aGVHD) The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) Learn More

Participate in a Clinical Trial

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More

Get our latest Vita stories in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring Vita list